Cargando…
Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L
After almost two years from its first evidence, the COVID-19 pandemic continues to afflict people worldwide, highlighting the need for multiple antiviral strategies. SARS-CoV-2 main protease (Mpro/3CLpro) is a recognized promising target for the development of effective drugs. Because single target...
Autores principales: | Costanzi, Elisa, Kuzikov, Maria, Esposito, Francesca, Albani, Simone, Demitri, Nicola, Giabbai, Barbara, Camasta, Marianna, Tramontano, Enzo, Rossetti, Giulia, Zaliani, Andrea, Storici, Paola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583849/ https://www.ncbi.nlm.nih.gov/pubmed/34769210 http://dx.doi.org/10.3390/ijms222111779 |
Ejemplares similares
-
A Blueprint for High Affinity SARS-CoV-2 Mpro
Inhibitors from Activity-Based Compound Library Screening Guided by
Analysis of Protein Dynamics
por: Gossen, Jonas, et al.
Publicado: (2021) -
A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition
por: Heilmann, Emmanuel, et al.
Publicado: (2022) -
Easy access to α-ketoamides as SARS-CoV-2 and MERS M(pro) inhibitors via the PADAM oxidation route
por: Pelliccia, Sveva, et al.
Publicado: (2022) -
Identification of Inhibitors of SARS-CoV-2
3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing
Screen
por: Kuzikov, Maria, et al.
Publicado: (2021) -
Natural Products-Based Drug Design against SARS-CoV-2 Mpro 3CLpro
por: Silva, Rai C., et al.
Publicado: (2021)